FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:740 August 18, 2005 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Ramaekers, V. T. PubMed Citation

To the Editor: Ramaekers et al. (May 12 issue)¹ report 28 patients with the cerebral folate deficiency syndrome characterized by decreased levels of 5-methyltetrahydrofolate (5MTHF) in the cerebrospinal fluid caused by autoantibodies' blocking of folate transport into the brain. The patients benefited from folinic acid supplementation.

The clinical features of this syndrome fit with other neurodegenerative disorders. According to previous papers by the authors, the latter disorders can be associated with cerebral folate deficiency as a secondary phenomenon.^2,3,4 Patients with secondary cerebral folate deficiency (e.g., the Rett syndrome) potentially benefit from folinic acid supplementation.^2,3,4 The authors do not report the . . . [Full Text of this Article]

This article has been cited by other articles:

• Pichelmayer, O, Gruenberger, B, Zielinski, C, Raderer, M (2006). Bevacizumab is active in malignant effusion. Ann Oncol 17: 1853-1853 [Full Text]  
• Knutson, K. L., Krco, C. J., Erskine, C. L., Goodman, K., Kelemen, L. E., Wettstein, P. J., Low, P. S., Hartmann, L. C., Kalli, K. R. (2006). T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer. JCO 24: 4254-4261 [Abstract] [Full Text]